Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Pancreatic Neoplasms 113 Urinary Bladder Neoplasms 56 Carcinoma, Non-Small-Cell Lung 52 Cholangiocarcinoma 33 Biliary Tract Neoplasms 32 Neoplasm Metastasis 30 Ovarian Neoplasms 27 Lymphoma, Large B-Cell, Diffuse 26 Breast Neoplasms 25 Lung Neoplasms 24 Neoplasms 23 Carcinoma, Transitional Cell 23 Triple Negative Breast Neoplasms 22 Nasopharyngeal Carcinoma 21 Colorectal Neoplasms 20 Recurrence 17 Non-Muscle Invasive Bladder Neoplasms 16 Gallbladder Neoplasms 15 Fallopian Tube Neoplasms 15 Sarcoma 13 Bile Duct Neoplasms 11 Parkinson Disease 4, Autosomal Dominant Lewy Body 10 Hodgkin Disease 10 Lymphoma 9 Uterine Cervical Neoplasms 8 Adenocarcinoma 8 Stomach Neoplasms 7 Lymphoma, Non-Hodgkin 7 Endometrial Neoplasms 7 Nasopharyngeal Neoplasms 6

Interventions

pembrolizumab 2 poly(I).poly(c12,U) 1 liposomal doxorubicin 1 Platinum Compounds 1 Paclitaxel 1 Gemcitabine 1 Cisplatin 1 Carboplatin 1 Bevacizumab 1 1-dodecylpyridoxal 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Ovarian Cancer Recurrent × Gemcitabine × 1 year × Clear all

NCT06843447 2026-05-26

MK-5909-003

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting

Ovarian Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon ⚡